120 related articles for article (PubMed ID: 24012472)
1. Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer.
Schrader AJ; Seseke S; Keil C; Herrmann E; Goebell PJ; Weikert S; Steffens S; Bergmann L; Roigas J; Steiner T
Eur Urol; 2014 Aug; 66(2):275-81. PubMed ID: 24012472
[TBL] [Abstract][Full Text] [Related]
2. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
[TBL] [Abstract][Full Text] [Related]
3. Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.
Afshar M; Pascoe J; Whitmarsh S; James N; Porfiri E
Drug Des Devel Ther; 2015; 9():13-9. PubMed ID: 25552898
[TBL] [Abstract][Full Text] [Related]
4. Temsirolimus in renal cell carcinoma.
Otto T; Eimer C; Gerullis H
Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.
Lamm W; Vogl UM; Bojic M; Zielinski C; Klingler C; Kramer G; Schmidinger M
Acta Oncol; 2012 Jan; 51(1):101-6. PubMed ID: 21736504
[TBL] [Abstract][Full Text] [Related]
6. Temsirolimus for advanced renal cell carcinoma.
Bergmann L; Maute L; Guschmann M
Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
[TBL] [Abstract][Full Text] [Related]
9. Temsirolimus: a safety and efficacy review.
Bukowski RM
Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
[TBL] [Abstract][Full Text] [Related]
10. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Ferté C; Koscielny S; Albiges L; Rocher L; Soria JC; Iacovelli R; Loriot Y; Fizazi K; Escudier B
Eur Urol; 2014 Apr; 65(4):713-20. PubMed ID: 23993162
[TBL] [Abstract][Full Text] [Related]
11. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.
Bergmann L; Goebell PJ; Kube U; Kindler M; Herrmann E; Janssen J; Schmitz J; Weikert S; Steiner G; Jakob A; Staehler MD; Steiner T; Overkamp F; Albrecht M; Guderian G; Doehn C
Onkologie; 2013; 36(3):95-100. PubMed ID: 23485996
[TBL] [Abstract][Full Text] [Related]
12. Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus.
Amato RJ; Flaherty A; Zhang Y; Ouyang F; Mohlere V
Urol Oncol; 2014 Apr; 32(3):345-54. PubMed ID: 24321256
[TBL] [Abstract][Full Text] [Related]
13. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.
Patil S; Ishill N; Deluca J; Motzer RJ
Cancer; 2010 Jan; 116(2):347-54. PubMed ID: 19921736
[TBL] [Abstract][Full Text] [Related]
14. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
Armstrong AJ; George DJ; Halabi S
J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
[TBL] [Abstract][Full Text] [Related]
15. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
Tafreshi A; Thientosapol E; Liew MS; Guo Y; Quaggiotto M; Boyer M; Davis ID
Asia Pac J Clin Oncol; 2014 Mar; 10(1):60-5. PubMed ID: 24152417
[TBL] [Abstract][Full Text] [Related]
17. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
[TBL] [Abstract][Full Text] [Related]
18. [Adverse events associated with temsirolimus for patients with metastatic renal cell carcinoma].
Miyake H; Fujisawa M
Hinyokika Kiyo; 2012 Nov; 58(11):651-4. PubMed ID: 23254795
[TBL] [Abstract][Full Text] [Related]
19. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
Tsimafeyeu I; Demidov L; Kharkevich G; Petenko N; Galchenko V; Sinelnikov I; Naidzionak U
Am J Clin Oncol; 2012 Jun; 35(3):251-4. PubMed ID: 21358295
[TBL] [Abstract][Full Text] [Related]
20. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
Paule B; Brion N
Anticancer Res; 2011 Jan; 31(1):331-3. PubMed ID: 21273619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]